Combination therapies: Innovative strategies for enhancing treatment outcomes

Nawal Hlal Almutairi; Nawal Ganai M Bahari; Alhanouf Zaid Almutairi; Mariam Sabr Alshameri; Hanadi Naji Alhajrasi; Faisal Nasser Alharbi; Manal Nasser Almasad; Nourah Hassan Alotaibi; Bashayer Ali Alshehri; Mashaal Nasser Almazroa; Zainab Ali Alqarni

doi:10.53730/ijhs.v7nS1.15028

Authors

Nawal Hlal Almutairi KSA, National Guard Health Affairs
Nawal Ganai M Bahari KSA, National Guard Health Affairs
Alhanouf Zaid Almutairi KSA, National Guard Health Affairs
Mariam Sabr Alshameri KSA, National Guard Health Affairs
Hanadi Naji Alhajrasi KSA, National Guard Health Affairs
Faisal Nasser Alharbi KSA, National Guard Health Affairs
Manal Nasser Almasad KSA, National Guard Health Affairs
Nourah Hassan Alotaibi KSA, National Guard Health Affairs
Bashayer Ali Alshehri KSA, National Guard Health Affairs
Mashaal Nasser Almazroa KSA, National Guard Health Affairs
Zainab Ali Alqarni KSA, National Guard Health Affairs

Keywords:

Tuberculosis, Combination treatment, Multidrug therapy, Antibiotics, Computer modeling

Abstract

Background: Tuberculosis (TB) is a significant global health issue requiring prolonged treatment regimens that often involve multiple medications. Mycobacterium tuberculosis, the causative agent, is capable of residing in various tissue compartments during infection, leading to variability in drug accessibility and susceptibility. The complexity of the infection necessitates the use of antibiotic combinations to ensure that all affected areas are effectively treated. Despite the importance of these combinations, their design has traditionally been addressed relatively late in the drug development process, leading to a limited number of evaluated drug combinations. Aim of Work: This study aims to examine the advancements made in the investigation of drug combinations for TB treatment through in vitro, in vivo, and computational approaches. It will also explore the potential integration of these methodologies with recent successful clinical trials of innovative medication combinations to enhance combination treatments for TB. Methods: We conducted thorough literature searches to identify and analyze the methodologies and experimental models utilized in the assessment of medication combinations for TB. This involved examining the capabilities of various in vitro, in vivo, and computational techniques that have been applied to study the interactions and effects of different antibiotic combinations.

Downloads

Download data is not yet available.

References

Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231–S279.

Kerantzas CA, Jacobs WR. Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. mBio. 2017;8(2):e01586–16.

Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med. 2007;4(3):e120.

World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.

Tiberi S, du Plessis N, Walzl G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018;18(7):e183–e198.

Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015 Apr 27;5(9):a017863.

Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021 May 6;384(18):1705–1718.

Conradie F, Diacon AH, Ngubane N, et al., Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. .

Riva MA. From milk to rifampicin and back again: history of failures and successes in the treatment for tuberculosis. J Antibiot (Tokyo). 2014;67(9):661–665.

Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J Suppl. 2002 Jul;36(Supplement 36):87s–94s.

Sensi P. History of the development of rifampin. Clin Infect Dis. 1983;5(Supplement_3):S402–S406.

Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642–1656.

Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2(1):16076.

Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb). 2011 Nov;91(6):497–509.

Orme IM, Basaraba RJ. The formation of the granuloma in tuberculosis infection. Semin Immunol. 2014;26(6):601–609.

Yegian D. Biology of tubercle bacilli in necrotic lesions. Am Rev Tuberc. 1952 Nov;66(5):629–631.

Sarathy JP, Dartois V. Caseum: a niche for Mycobacterium tuberculosis drug-tolerant persisters. Clin Microbiol Rev. 2020 Jun 17;33(3). DOI:10.1128/CMR.00159-19.

Xie YL, de Jager VR, Chen RY, et al., Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. Sci Transl Med. 2021;13(579):eabd7618. .

Strydom N, Gupta SV, Fox WS, et al. Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: a mechanistic model and tool for regimen and dose optimization. PLoS Med. 2019 Apr;16(4):e1002773.

Ernest JP, Sarathy J, Wang N, et al. Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis. Antimicrob Agents Chemother. 2021Jul12; 65(10). AAC0050621. DOI:10.1128/AAC.00506-21.

Sarathy J, Blanc L, Alvarez-Cabrera N, et al. Fluoroquinolone Efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations. Antimicrob Agents Chemother. 2019 May;63(5). DOI:10.1128/AAC.02516-18 .

Prideaux B, Via LE, Zimmerman MD, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 2015;21(10):1223–1227.

Sarathy JP, Zuccotto F, Hsinpin H, et al. Prediction of drug penetration in tuberculosis lesions. ACS Infect Dis. 2016;2(8):552–563.

Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol. 2001;55(1):139–163.

Lenaerts A, Barry CE 3rd, Dartois V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev. 2015 Mar;264(1):288–307.

Hoff DR, Ryan GJ, Driver ER, et al. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and Guinea pigs during disease progression and after drug treatment. PLoS One. 2011 Mar 21;6(3):e17550.

Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother. 2007 Sep;51(9):3338–3345.

Schrader SM, Vaubourgeix J, Nathan C. Biology of antimicrobial resistance and approaches to combat it. Sci Transl Med. 2020 Jun 24;12(549). DOI:10.1126/scitranslmed.aaz6992.

Eoh H, Liu R, Lim J, et al. Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in Mycobacterium tuberculosis. Front Cell Infect Microbiol. 2022;12:958240.

Iacobino A, Piccaro G, Giannoni F, et al. Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli. Int J Mycobacteriol. 2017 Jul-Sep;6(3):213–221.

Zhang M, Sala C, Dhar N, et al. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014 Jun;58(6):3217–3223.

Raghunandanan S, Jose L, Kumar RA. Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne’s model of dormancy. J Antibiot (Tokyo). 2018 Nov;71(11):939–949.

Betts JC, Lukey PT, Robb LC, et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol. 2002 Feb;43(3):717–731.

Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996 Jun;64(6):2062–2069.

Karakousis PC, Williams EP, Bishai WR. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother. 2008 Feb;61(2):323–331.

Iacobino A, Piccaro G, Giannoni F, et al. Activity of drugs against dormant Mycobacterium tuberculosis. Int J Mycobacteriol. 2016 Dec;5(Suppl 1):S94–S95.

Fattorini L, Piccaro G, Mustazzolu A, et al. Targeting dormant bacilli to fight tuberculosis. Mediterr J Hematol Infect Dis. 2013 Nov 19;5(1):e2013072.

Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005 Jan 14;307(5707):223–227.

Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008 Nov 28;322(5906):1392–1395.

Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397–2405.

Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810–823.

Bryk R, Gold B, Venugopal A, et al. Selective killing of nonreplicating mycobacteria. Cell Host Microbe. 2008 Mar 13;3(3):137–145.

Darby CM, Nathan CF. Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline. J Antimicrob Chemother. 2010;65(7):1424–1427.

Grant SS, Kawate T, Nag PP, et al. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem Biol. 2013 Oct 18;8(10):2224–2234.

Gold B, Smith R, Nguyen Q, et al. Novel cephalosporins selectively active on nonreplicating Mycobacterium tuberculosis. J Med Chem. 2016;59(13):6027–6044.

Chatterjee D, Bonnett SA, Dennison D, et al. A class of hydrazones are active against non-replicating Mycobacterium tuberculosis. PLoS One. 2018;13(10). DOI:10.1371/journal.pone.0196348.

Neyrolles O, Flint L, Korkegian A, et al. InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis. PLoS One. 2020;15(11):e0239354.

Balaban NQ, Helaine S, Lewis K, et al. Definitions and guidelines for research on antibiotic persistence. Nature Rev Microbiol. 2019;17(7):441–448.

Aldridge BB, Fernandez-Suarez M, Heller D, et al. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. Science. 2012 Jan 6;335(6064):100–104.

Schrader SM, Botella H, Jansen R, et al. Multiform antimicrobial resistance from a metabolic mutation. Sci Adv. 2021 Aug;7(35). doi:10.1126/sciadv.abh2037.

Levin-Reisman I, Ronin I, Gefen O, et al. Antibiotic tolerance facilitates the evolution of resistance. Science. 2017 Feb 24;355(6327):826–830.

Liu J, Gefen O, Ronin I, et al. Effect of tolerance on the evolution of antibiotic resistance under drug combinations. Science. 2020 Jan 10;367(6474):200–204.

McGrath M, Gey van Pittius NC, van Helden PD, et al. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014 Feb;69(2):292–302.

Ford CB, Shah RR, Maeda MK, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 2013 Jul;45(7):784–790.

Coelho T, Machado D, Couto I, et al. Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. Front Microbiol. 2015;6:330.

Laws M, Jin P, Rahman KM. Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance. Trends Microbiol. 2022;30(1):57–68.

Pyle MM. Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. Proc Staff Meet Mayo Clin. 1947 Oct 15;22(21):465–473.

Palaci M, Dietze R, Hadad DJ, et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol. 2007 Dec;45(12):4064–4066.

British Medical Journal. Streptomycin treatment of pulmonary tuberculosis: a medical research council investigation. Bmj. 1948;2(4582):769–782.

Bahuguna A, Rawat DS. An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev. 2020 Jan;40(1):263–292.